Ultragenyx Pharmaceutical P/S 2024

Ultragenyx Pharmaceutical Aktienanalyse

What does Ultragenyx Pharmaceutical do?

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company that focuses on developing therapies for rare diseases. The company was founded in 2010 and is headquartered in Novato, California. The history of Ultragenyx began when the founder and CEO Emil Kakkis recognized the lack of medications for rare diseases. These diseases often affect a very small number of patients and there are few or no established treatment options. Ultragenyx decided to fill this gap and has been working since its inception to find new ways to develop therapies for rare diseases. The company's business model is based on utilizing innovative approaches to develop therapies for rare diseases and building close relationships with patient communities. Ultragenyx is divided into different divisions to address various disease areas. The largest division focuses on developing therapies for lysosomal storage diseases. These are a group of rare, inherited diseases caused by a deficiency of enzymes needed for the proper functioning of lysosomes in the body. Ultragenyx has developed several products in the field of lysosomal storage diseases, including an enzyme replacement therapy for the treatment of mucopolysaccharidosis VII, a rare metabolic disorder caused by a deficiency of the enzyme beta-glucuronidase. The company has also developed an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI. Another division of Ultragenyx focuses on developing therapies for genetically inherited metabolic disorders. These diseases are caused by mutations in genes that are responsible for important metabolic processes in the body. Ultragenyx has several drugs in the pipeline that focus on the treatment of genetically inherited metabolic disorders. Ultragenyx also has a division that focuses on the treatment of central nervous system (CNS) diseases. The company is working on therapies for various rare neurological disorders, including X-linked adrenoleukodystrophy and glycogen storage disease type II. Ultragenyx has developed flexible development platforms to quickly respond to the needs of patients with rare diseases. The company works closely with patient communities to receive feedback on medications and development plans. This helps the company to quickly address patient concerns and requirements and develop better therapies. Overall, Ultragenyx Pharmaceutical Inc. has a clear vision that is attributed to its business model and innovation culture. The company is committed to developing therapies for people with rare diseases that contribute to improving their quality of life. Ultragenyx has an impressive pipeline of drugs and is well positioned to continue to grow in the future and develop innovative therapies for rare diseases. Ultragenyx Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Ultragenyx Pharmaceutical's P/S Ratio

Ultragenyx Pharmaceutical's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Ultragenyx Pharmaceutical's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Ultragenyx Pharmaceutical's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Ultragenyx Pharmaceutical’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Ultragenyx Pharmaceutical stock

What is the price-to-earnings ratio of Ultragenyx Pharmaceutical?

The price-earnings ratio of Ultragenyx Pharmaceutical is currently 5.53.

How has the price-earnings ratio of Ultragenyx Pharmaceutical changed compared to last year?

The price-to-earnings ratio of Ultragenyx Pharmaceutical has increased by -34.17% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Ultragenyx Pharmaceutical high compared to other companies?

Yes, the price-to-earnings ratio of Ultragenyx Pharmaceutical is high compared to other companies.

How does an increase in the price-earnings ratio of Ultragenyx Pharmaceutical affect the company?

An increase in the price-earnings ratio of Ultragenyx Pharmaceutical would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Ultragenyx Pharmaceutical affect the company?

A decrease in the price-earnings ratio of Ultragenyx Pharmaceutical would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Ultragenyx Pharmaceutical?

Some factors that influence the price-earnings ratio of Ultragenyx Pharmaceutical are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Ultragenyx Pharmaceutical pay?

Over the past 12 months, Ultragenyx Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ultragenyx Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Ultragenyx Pharmaceutical?

The current dividend yield of Ultragenyx Pharmaceutical is .

When does Ultragenyx Pharmaceutical pay dividends?

Ultragenyx Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Ultragenyx Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ultragenyx Pharmaceutical located?

Ultragenyx Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ultragenyx Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ultragenyx Pharmaceutical from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Ultragenyx Pharmaceutical pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Ultragenyx Pharmaceutical in the year 2023?

In the year 2023, Ultragenyx Pharmaceutical distributed 0 USD as dividends.

In which currency does Ultragenyx Pharmaceutical pay out the dividend?

The dividends of Ultragenyx Pharmaceutical are distributed in USD.